RAYMOND JAMES & ASSOCIATES - HALOZYME THERAPEUTICS INC ownership

HALOZYME THERAPEUTICS INC's ticker is HALO and the CUSIP is 40637H109. A total of 357 filers reported holding HALOZYME THERAPEUTICS INC in Q3 2022. The put-call ratio across all filers is 0.48 and the average weighting 0.2%.

Quarter-by-quarter ownership
RAYMOND JAMES & ASSOCIATES ownership history of HALOZYME THERAPEUTICS INC
ValueSharesWeighting
Q3 2023$2,953,654
+5.1%
77,321
-0.7%
0.00%0.0%
Q2 2023$2,809,990
-31.2%
77,904
-27.2%
0.00%
-50.0%
Q1 2023$4,085,444
-31.2%
106,977
+2.5%
0.00%
-20.0%
Q4 2022$5,940,360
+100.7%
104,400
+39.5%
0.01%
+66.7%
Q3 2022$2,960,000
+61.3%
74,854
+79.5%
0.00%
+50.0%
Q2 2022$1,835,000
+37.8%
41,705
+24.9%
0.00%
+100.0%
Q1 2022$1,332,000
-35.3%
33,401
-34.8%
0.00%
-50.0%
Q4 2021$2,059,000
+44.0%
51,194
+45.7%
0.00%
+100.0%
Q3 2021$1,430,000
-12.1%
35,145
-1.8%
0.00%0.0%
Q2 2021$1,626,000
+29.2%
35,807
+18.5%
0.00%0.0%
Q1 2021$1,259,000
-38.8%
30,210
-37.3%
0.00%
-50.0%
Q4 2020$2,056,000
+156.0%
48,150
+57.5%
0.00%
+100.0%
Q3 2020$803,000
+32.3%
30,565
+35.0%
0.00%0.0%
Q2 2020$607,000
+53.3%
22,643
+2.9%
0.00%0.0%
Q1 2020$396,000
-6.2%
21,998
-7.6%
0.00%0.0%
Q4 2019$422,000
+14.7%
23,813
+0.4%
0.00%0.0%
Q3 2019$368,000
+35.3%
23,729
+58.3%
0.00%
Q3 2018$272,000
+22.5%
14,988
+14.0%
0.00%
Q2 2018$222,000
+2.8%
13,151
+23.1%
0.00%
Q4 2017$216,000
+52.1%
10,685
-9.2%
0.00%
Q3 2016$142,000
+40.6%
11,770
+0.9%
0.00%
Q2 2016$101,000
-10.6%
11,670
-2.5%
0.00%
Q1 2016$113,000
-45.4%
11,9700.0%0.00%
-100.0%
Q4 2015$207,000
-7.2%
11,970
-27.8%
0.00%0.0%
Q3 2015$223,000
-39.1%
16,570
+2.3%
0.00%0.0%
Q2 2015$366,000
-15.3%
16,200
-46.4%
0.00%
-50.0%
Q1 2015$432,000
+63.6%
30,250
+10.4%
0.00%
+100.0%
Q4 2014$264,000
+22.2%
27,400
+15.6%
0.00%0.0%
Q3 2014$216,000
-1.4%
23,700
+6.8%
0.00%0.0%
Q2 2014$219,000
+5.3%
22,200
+35.4%
0.00%0.0%
Q1 2014$208,000
-13.3%
16,400
+2.5%
0.00%
-50.0%
Q4 2013$240,00016,0000.00%
Other shareholders
HALOZYME THERAPEUTICS INC shareholders Q3 2022
NameSharesValueWeighting ↓
SNYDER CAPITAL MANAGEMENT L P 4,324,232$165,185,6623.73%
Steamboat Capital Partners, LLC 196,898$7,521,5042.79%
2Xideas AG 600,799$22,950,5222.54%
BERNZOTT CAPITAL ADVISORS 171,808$6,563,0662.26%
Redwood Investments, LLC 328,459$12,547,1341.70%
Mesirow Institutional Investment Management, Inc. 380,415$14,531,8531.47%
Granite Investment Partners, LLC 856,253$32,708,8651.37%
Penn Capital Management Company, LLC 324,707$12,453,2111.28%
EFG Asset Management (North America) Corp. 137,739$5,262,3191.25%
First Light Asset Management, LLC 313,536$11,977,0751.14%
View complete list of HALOZYME THERAPEUTICS INC shareholders